Managing adverse events in the use of bevacizumab and chemotherapy.

2.50
Hdl Handle:
http://hdl.handle.net/10541/69597
Title:
Managing adverse events in the use of bevacizumab and chemotherapy.
Authors:
Blowers, Elaine; Hall, Kate
Abstract:
The anti-angiogenic agent bevacizumab (Avastin) has received regulatory approval for the treatment of metastatic breast cancer (MBC) in combination with the taxane chemotherapy agent paclitaxel. A range of side-effects associated with this agent have been identified across different tumour types; these are known to differ from those frequently reported with chemotherapy agents. This article is part one of a two-part literature review that was conducted to provide insight into the range, frequency and severity of adverse events that arise specifically in breast cancer when bevacizumab is combined with cytotoxic chemotherapy. PubMed and the websites of oncology conferences were searched to identify studies of bevacizumab plus chemotherapy in patients with MBC. Seventeen studies met the search criteria, including 3,836 bevacizumab-treated patients. Side-effects associated with bevacizumab included hypertension, proteinuria, thromboembolic events, bleeding and cardiac toxicity. Part two of the series will appear in the next issue of BJN.
Affiliation:
Christie Hospital NHS Foundation Trust, Manchester.
Citation:
Managing adverse events in the use of bevacizumab and chemotherapy., 18 (6):351-6, 358 Br J Nurs
Journal:
British Journal of Nursing
Issue Date:
Feb-2009
URI:
http://hdl.handle.net/10541/69597
PubMed ID:
19329899
Type:
Article
Language:
en
ISSN:
0966-0461
Appears in Collections:
All Christie Publications ; Medical Oncology

Full metadata record

DC FieldValue Language
dc.contributor.authorBlowers, Elaine-
dc.contributor.authorHall, Kate-
dc.date.accessioned2009-06-02T14:03:05Z-
dc.date.available2009-06-02T14:03:05Z-
dc.date.issued2009-02-
dc.identifier.citationManaging adverse events in the use of bevacizumab and chemotherapy., 18 (6):351-6, 358 Br J Nursen
dc.identifier.issn0966-0461-
dc.identifier.pmid19329899-
dc.identifier.urihttp://hdl.handle.net/10541/69597-
dc.description.abstractThe anti-angiogenic agent bevacizumab (Avastin) has received regulatory approval for the treatment of metastatic breast cancer (MBC) in combination with the taxane chemotherapy agent paclitaxel. A range of side-effects associated with this agent have been identified across different tumour types; these are known to differ from those frequently reported with chemotherapy agents. This article is part one of a two-part literature review that was conducted to provide insight into the range, frequency and severity of adverse events that arise specifically in breast cancer when bevacizumab is combined with cytotoxic chemotherapy. PubMed and the websites of oncology conferences were searched to identify studies of bevacizumab plus chemotherapy in patients with MBC. Seventeen studies met the search criteria, including 3,836 bevacizumab-treated patients. Side-effects associated with bevacizumab included hypertension, proteinuria, thromboembolic events, bleeding and cardiac toxicity. Part two of the series will appear in the next issue of BJN.en
dc.language.isoenen
dc.subjectBreast Canceren
dc.subjectBevacizumaben
dc.subjectNurse Educationen
dc.subjectSide Effectsen
dc.subject.meshAngiogenesis Inhibitors-
dc.subject.meshAntibodies, Monoclonal-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshBreast Neoplasms-
dc.subject.meshClinical Trials, Phase III as Topic-
dc.subject.meshDrug Approval-
dc.subject.meshHeart Diseases-
dc.subject.meshHemorrhage-
dc.subject.meshHumans-
dc.subject.meshHypertension-
dc.subject.meshIntestinal Perforation-
dc.subject.meshPaclitaxel-
dc.subject.meshProteinuria-
dc.subject.meshResearch Design-
dc.subject.meshSafety-
dc.subject.meshSeverity of Illness Index-
dc.subject.meshThromboembolism-
dc.subject.meshTreatment Outcome-
dc.titleManaging adverse events in the use of bevacizumab and chemotherapy.en
dc.typeArticleen
dc.contributor.departmentChristie Hospital NHS Foundation Trust, Manchester.en
dc.identifier.journalBritish Journal of Nursingen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.